NPC1 and AL amyloidosis: Notably, U18666A, an NPC1 inhibitor, significantly enhanced the therapeutic efficacy of conventional chemotherapy in established multiple myeloma (MM) and solid tumors, highlighting the potential for NPC1 inhibitors as promising novel chemotherapeutic agents.